Latest Conference Coverage


Kumar Budur, MD, MS  (Credit: LinkedIn)

Pitolisant Reduces Excessive Daytime Sleepiness and Fatigue in Myotonic Dystrophy Type 1

June 27th 2024

Additional data of a phase 2 study presented at the 2024 SLEEP Annual Meeting demonstrated that pitolisant significantly improved in secondary end points among patients with myotonic dystrophy type 1.


Istradefylline Shows Promising Effects as Treatment for Tremor in Parkinson Disease

Istradefylline Shows Promising Effects as Treatment for Tremor in Parkinson Disease

June 27th 2024

Istradefylline led to significant reductions in tremor and motor symptoms in patients with Parkinson disease over 24 weeks.


Michael Soileau, MD, FAAN

Advancements in Multidisciplinary Parkinson Disease Treatment: Michael Soileau, MD, FAAN

June 26th 2024

The movement disorder specialist at Texas Movement Disorder Specialists talked about a comprehensive panel discussion that highlighted the evolution of Parkinson disease treatment. [WATCH TIME: 4 minutes]


Patricia Clark, CNP

Enhancing Hospital Care for Patients With Parkinson Disease: Patricia Clark, CNP

June 26th 2024

The nurse practitioner at the Cleveland Clinic talked about a specialized program involving nurse practitioners that aims to improve inpatient care quality and safety for patients with Parkinson disease. [WATCH TIME: 5 minutes]


NeuroVoices: Sanjay R. Patel, MD, MS, on Advances in Pharmaceutical Treatment for Sleep Apnea

NeuroVoices: Sanjay R. Patel, MD, MS, on Advances in Pharmaceutical Treatment for Sleep Apnea

Published: June 26th 2024 | Updated: June 26th 2024

The director of the Center for Sleep and Cardiovascular Outcomes Research at University of Pittsburgh talked about a phase 3 trial assessing a pharmaceutical treatment, AD109, in sleep apnea.


Phase 2 SUNRISE-PD Trial to Test Investigational Bezisterim as Disease-Modifying Therapy for Parkinson

Phase 2 SUNRISE-PD Trial to Test Investigational Bezisterim as Disease-Modifying Therapy for Parkinson

June 25th 2024

Bezisterim has shown potential in improving non-motor symptoms like fatigue and sleep issues, with promising results from previous studies.


Small-Scale Trial of Pimavanserin Highlights Modified Functional Status Questionnaire as Reliable Tool for Parkinson Disease Psychosis

Small-Scale Trial of Pimavanserin Highlights Modified Functional Status Questionnaire as Reliable Tool for Parkinson Disease Psychosis

June 25th 2024

Modified Functional Status Questionnaire, an assessment of activities of daily living, includes several different notable domains, including quality of interaction, social activity, and psychological function.


R. Scott Turner, PhD, MD, FANA, FAAN

Amyloid and Non-Amyloid Advanced Therapeutics in Dementia: R. Scott Turner, PhD, MD, FANA, FAAN

June 25th 2024

The director of the Memory Disorders Program at Georgetown University talked about newly approved anti-amyloid antibodies that show significant promise in slowing Alzheimer disease progression. [WATCH TIME: 5 minutes]


Better Safety Profile Observed With Istradefylline Over Amantadine Extended-Release and COMT Inhibitors

Better Safety Profile Observed With Istradefylline Over Amantadine Extended-Release and COMT Inhibitors

June 25th 2024

Although the data used predated 2019, istradefylline was associated with a statistically significant lower odds of the overall incidence of treatment-emergent adverse events than other adjunctive therapies for Parkinson disease.


Patients With Essential Tremor Report High Levels of Dissatisfaction With Treatment Options

Patients With Essential Tremor Report High Levels of Dissatisfaction With Treatment Options

June 24th 2024

In a large-scale analysis. 70% of patients with essential tremor and 70% of undiagnosed patients reported dissatisfaction with the therapeutic options available to treat their condition.


Charbel Moussa, MBBS, PhD

Disease-Modifying Therapies for Dementia in Movement Disorders: Charbel Moussa, MBBS, PhD

June 24th 2024

The associate professor of neurology at Georgetown University Medical Center talked about disease-modifying therapies for movement disorder-related dementia that aim to address the underlying mechanisms of the disease. [WATCH TIME: 5 minutes]


Kelly Papesh, DNP, APRN, FNP-BC

Overcoming Barriers in Communication for Patient Disclosure in Movement Disorders: Kelly Papesh, DNP, APRN, FNP-BC

June 24th 2024

The executive director of the Association of Movement Disorder Advanced Practice Providers talked about the need for improved communication and trust of the patient-provider relationship in the field of movement disorders. [WATCH TIME: 3 minutes]


Anvi Gadani, MD

Advanced Therapeutic Options for Parkinson Disease and Essential Tremor: Anvi Gadani, MD

Published: June 24th 2024 | Updated: July 24th 2024

The assistant clinical professor of medicine at Medstar Georgetown University Hospital talked about her presentation at ATMRD where she covered various advanced therapies for managing Parkinson disease and essential tremor. [WATCH TIME: 5 minutes]


Role of Sleep Chronotype, Circadian Rhythm in Neurocognitive Health: Ashley Curtis, PhD

Role of Sleep Chronotype, Circadian Rhythm in Neurocognitive Health: Ashley Curtis, PhD

June 22nd 2024

The assistant professor at the University of South Florida provided perspective on the influence of circadian rhythm in neurocognitive health and the possibilities of screening for circadian rhythm issues for large-scale clinical trials. [WATCH TIME: 4 minutes]


Understanding the Importance of Maternal-Fetal Circadian Synchrony

Understanding the Importance of Maternal-Fetal Circadian Synchrony

June 20th 2024

Eric Herzog, PhD, a chronobiologist and professor of biology and neuroscience at Washington University, provided thoughts on a number of topics related to sleep during pregnancy and the significance of maintaining circadian rhythms.


Eliciting Patient Voice to Help Optimize the Treatment and Management of Cataplexy: Anne Marie Morse, DO, FAASM

Eliciting Patient Voice to Help Optimize the Treatment and Management of Cataplexy: Anne Marie Morse, DO, FAASM

June 18th 2024

The pediatric neurologist and sleep medicine specialist at Geisinger Medical Center provided commentary on the complexities with treating cataplexy, and the misperceptions patients may have about how to manage their condition. [WATCH TIME: 3 minutes]


A Personalized Approach to Treating Gait Issues in Multiple Sclerosis: the Cionic Neural Sleeve

A Personalized Approach to Treating Gait Issues in Multiple Sclerosis: the Cionic Neural Sleeve

June 17th 2024

Douglas A. Wadja, PhD, an assistant professor of neurology at Cleveland State University, detailed a study assessing an electrical nerve stimulation approach to alleviate gait dysfunction in patients with MS.


Therapeutic Potential of Orexin Agonist ALKS 2680 on Display at SLEEP 2024

Therapeutic Potential of Orexin Agonist ALKS 2680 on Display at SLEEP 2024

June 15th 2024

Ron Grunstein, MD, PhD, head of Sleep and Circadian Research at the Woolcock Institute of Medical Research, provided commentary on early, promising data regarding investigational agent ALKS 2680 in patients with narcolepsy type 1.


Episode 117: 2024 Consortium of Multiple Sclerosis Centers Annual Meeting Highlights

Episode 117: 2024 Consortium of Multiple Sclerosis Centers Annual Meeting Highlights

June 14th 2024

Mind Moments®, a podcast from NeurologyLive®, brings you exclusive interviews with Anthony Feinstein, PhD, FRCPC, MBBCh; Brian G. Weinshenker, MD; Douglas A. Wajda, PhD; Le Hua, MD; and Eoin P. Flanagan, MB, BCh. [LISTEN TIME: 22 minutes]


Sanjay R. Patel, MD, MS

Promising Developments in Pharmaceutical Treatments for Sleep Apnea: Sanjay R. Patel, MD, MS

June 13th 2024

The director of the Center for Sleep and Cardiovascular Outcomes Research at University of Pittsburgh talked about a novel pharmacologic treatment that shows potential as an alternative to continuous positive airway pressure for sleep apnea. [WATCH TIME: 5 minutes]


Using the Cionic Neural Sleeve to Alleviate Gait Dysfunction in Multiple Sclerosis: Douglas A. Wajda, PhD

Using the Cionic Neural Sleeve to Alleviate Gait Dysfunction in Multiple Sclerosis: Douglas A. Wajda, PhD

June 13th 2024

The assistant professor of neurology at Cleveland State University provided perspective on an early-stage study assessing the impacts of a functional electrical stimulation approach to treat gait problems in multiple sclerosis. [WATCH TIME: 4 minutes]


Closing the Gaps in Underserved Multiple Sclerosis Communities: Yahaira Rivera, MBEd

Closing the Gaps in Underserved Multiple Sclerosis Communities: Yahaira Rivera, MBEd

June 12th 2024

The director of Mission Delivery and Program Development for the Multiple Sclerosis Association of America provided perspective on a study presented at CMSC 2024 highlighting factors that play a role in access to resources and healthcare for patients with MS. [WATCH TIME: 3 minutes]


Using Social Listening Analyses to Better Characterize Patient Experiences With Narcolepsy: Anne Marie Morse, DO, FAASM

Using Social Listening Analyses to Better Characterize Patient Experiences With Narcolepsy: Anne Marie Morse, DO, FAASM

Published: June 12th 2024 | Updated: June 12th 2024

The pediatric neurologist and sleep medicine specialist at Geisinger Medical Center discussed a presentation from SLEEP 2024 highlighting the impacts of narcolepsy and how patients try to mitigate their symptoms. [WATCH TIME: 5 minutes]


NeuroVoices: William L. Conte, MD, MS, on Improving Care for LGBTQ+ Patients With Multiple Sclerosis

NeuroVoices: William L. Conte, MD, MS, on Improving Care for LGBTQ+ Patients With Multiple Sclerosis

June 12th 2024

The head of the MS Center at Methodist Hospitals discussed the need for inclusive and affirming healthcare practices for patients with multiple sclerosis who identify as LGBTQ+.


Patricia K. Coyle, MD

Updates in the Diagnosis and Management of Primary Progressive Multiple Sclerosis: Patricia K. Coyle, MD

Published: June 11th 2024 | Updated: June 11th 2024

The professor of neurology at Stony Brook Medicine talked about the diagnosis of primary progressive multiple sclerosis, a unique MS phenotype characterized by a gradual deterioration without initial attack. [WATCH TIME: 5 minutes]


Aliza Ben-Zacharia, PhD, DNP, ANP-BC, FAAN

Localization and Puzzling Together the Bigger Picture in Multiple Sclerosis: Aliza Ben-Zacharia, PhD, DNP, ANP-BC, FAAN

June 10th 2024

The assistant professor at Hunter College emphasized the important role of localization and accurately identifying the origin of neurological symptoms when diagnosing and managing multiple sclerosis. [WATCH TIME: 7 minutes]

© 2025 MJH Life Sciences

All rights reserved.